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Abstract
Background: Personal health information and biospecimens are valuable research resources essential for the
advancement of medicine and protected by national standards and provincial statutes. Research ethics and
privacy standards attempt to balance individual interests with societal interests. However these standards may not
reflect public opinion or preferences. The purpose of this study was to assess the opinions and preferences of
patients with kidney disease about the use of their health information and biospecimens for medical research.
Methods: A 45-item survey was distributed to a convenience sample of patients at an outpatient clinic in a large
urban centre. The survey briefly addressed sociodemographic and illness characteristics. Opinions were sought on
the research use of health information and biospecimens including consent preferences.
Results: Two hundred eleven of 400 distributed surveys were completed (response rate 52.8 %). Respondents
were generally supportive of medical research and trusting of researchers. Many respondents supported the use of
their information and biospecimens for health research and also preferred consent be sought for use of health
information and biospecimens. Some supported the use of their information and biospecimens for research
without consent. There were significant differences in the opinions people offered regarding the research use of
biospecimens compared to health information. Some respondent perspectives about consent were at odds with
current regulatory and legal standards.
Conclusions: Clinical health data and biospecimens are valuable research resources, critical to the advancement
of medicine. Use of these data for research requires balancing respect for individual autonomy, privacy and the
societal interest in the greater good. Incongruence between some respondent perspectives and the regulatory
standards suggest both a need for public education and review of legislation to increase understanding and
ensure the public’s trust is maintained.
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Background
Research using personal health information and biospe-
cimens is central to the advancement of medicine. Elec-
tronic health records and clinical biobanks are rich data
sources that can be used for secondary, research purposes.
In Canada, academic researchers affiliated with institu-
tions receiving federal funds must comply with the ethics
standards articulated in the TriCouncil Policy Statement 2
(TCPS2) [1]. Research using health information must also
comply with provincial privacy statues [2].
Disclosure of health information initially collected in
a clinical context is regulated by the Health Informa-
tion Act (HIA) in Alberta and by similar statutes across
Canada [2, 3]. The HIA permits disclosure of identifi-
able health information for research if certain condi-
tions are met, including proposal review by a Research
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Ethics Board (REB) (s. 49) and consideration of the
need for consent (s 50). Where consent is necessary, a
number of conditions must be satisfied (s. 34). First,
the consent must be provided in writing or electronic-
ally. The consent must also contain: an authorization
for disclosure, the purpose of the disclosure, the iden-
tity of the person to whom it will be disclosed, an ac-
knowledgement that the subject of the information is
aware of why the information is needed, the risks and
benefits associated with consent, the date on which the
consent is effective, the date on which it expires (if any)
and lastly, a statement that the consent may be revoked at
any time. The HIA does not permit surrogates, such as
family members or spouses, to provide consent unless a
specific personal (research) directive is in place (s. 104).
In certain circumstances, the REB may determine that
consent is not required (s. 50). For consent to be waived,
the REB must find that the public interest outweighs the
individual privacy interests, the researchers are qualified
to carry out the research, privacy and confidentiality
safeguards are in place and to obtain consent would be
unreasonable, impractical or not feasible.
Characteristics of the research that might preclude
consent include extremely large sample sizes, conditions
with high mortality rates, or health information from a
period in the past where it is likely most of the individ-
uals would be lost to follow up in the present day. Fi-
nally, consent is not required where the information
released is non-identifying (s 32(1)). Consistent with
the law, TCPS2 emphasizes the importance of informed
consent, but also identifies circumstances where non-
consensual research may be permitted. The two stan-
dards differ with respect to the permissibility of surro-
gate consents and the form the consent must take.
Human biological materials, such as organ/tissue samples,
bodily fluids or wastes, are also collected for clinical pur-
poses, but may be accessed for secondary use as research
materials. The removal of tissues is regulated in Alberta
under the Hospitals Act [4]. Under the Hospitals Act, surgi-
cally removed tissue must be submitted to a pathologist and
then stored for specified periods. The provincial laboratory
retains what it needs for clinical purposes but generally has
excess amounts that are repurposed for research use.
In contrast to health information, there are no laws
that govern the research use of human biological mate-
rials but ethics oversight in the form of REB review is
required under the TCPS 2 (2014). Similar to health
information, where biospecimens are de-identified, indi-
vidual consents are not required for their use in research.
If the materials are identifiable, researchers must seek an
informed consent unless several, specific conditions are
met [1].
While these provisions are clear, Canadian legal prece-
dent has found that human tissue removed for medical
tests becomes the property of the hospital where the pro-
cedure was performed, potentially limiting Canadians’
ability to decide what is done with their biological mate-
rials. This is consistent with the situation in the United
States, where since the 1990’s patients are considered to
have given up their rights to excised tissue. However,
proposed new regulations may challenge this [5–7].
Both health information and biological specimens are
valuable sources of research data. These resources can
be sought on a study-by-study basis directly from indi-
viduals, or can be stored in data registries in the case of
health information, or biobanks in the case of biological
samples. Stewardship of the material then rests with cus-
todians of the registries and biobanks. There has been
much written on research use of health information and
biospecimens [8–12]. Public opinion with respect to the
use of health information and biospecimens is varied, with
diversity of opinion reflected in beliefs about consent and
related issues [8, 13–17]. Some prefer an opt-out approach
where research use is assumed unless people state other-
wise. Others prefer a broad, one time consent granting
access to all future uses of their information and biosam-
ples, while some prefer to provide consent each time their
data are accessed [11, 13, 15, 18].
Considerations influencing individual consent prefer-
ence include the nature of the data (i.e., health informa-
tion or biospecimens), who is accessing the information,
what the research is about and whether the information is
identifiable or not [11, 15, 19, 20]. In addition, the public’s
experience with health care and research are likely to in-
fluence perspectives as are sociodemographic characteris-
tics including education, gender and age [15–17, 20, 21].
Where consent is required, evidence suggests that
those consenting differ systematically from those who
decline, biasing research results [9, 22, 23]. Such infor-
mation is important as research ethics boards and data
custodians continue to grapple with how best to bal-
ance public rights with individual interests arising from
use of these research resources [10, 18]. Understanding
public opinion as it reflects the considerations research
ethics boards must make, particularly in the context of the
Health Information Act and TCPS2 will assist these bodies
in discharging their responsibilities. Specific patient groups
bring unique perspectives to these considerations.
This survey sought to assess the opinions of patients
with chronic kidney disease about the research use of
health information and biospecimens.
Methods
This study received approval from the Conjoint Health
Research Ethics Board, University of Calgary (REB15-
0095). Survey development was informed by the Health
Information Act of Alberta, the TriCouncil Policy State-
ment 2 (2014) and a literature review. Questions were
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specific to the research aims and the survey was refined
iteratively. Face and content validity were assessed by the
research team. The survey was subsequently reviewed by
6 external content experts (legal, ethics, privacy, research
administration). Finally, 10 outpatients participated in
cognitive interviews about the instrument’s clarity and
comprehensibility [24]. Recommendations for revision
were discussed and revisions were made based on consen-
sus of the research team.
The final survey (Additional file 1) contained 45
fixed-choice items about patient experiences and opin-
ions regarding health research and use of personal
health information and/or biospecimens for research
purposes as well as limited socio-demographic and ill-
ness information (e.g., gender, age, education, ethnicity,
income, illness severity). Prefacing the opinion state-
ments, participants were told to assume their health in-
formation/biospecimens would be kept secure with the
strongest data and privacy protections. They were also
advised that where data were described as de-identified,
this meant that researchers would not know from whom
the information came. An open-ended text box was pro-
vided for participants to comment on consent and re-
search use of their data and/or specimens. Participants
were given a one-page background information sheet that
described medical research, health information, biospeci-
mens and current regulatory context, including Research
Ethics Boards’ roles and responsibilities and HIA pro-
visions (Additional file 2).
Participant recruitment, using convenience sampling,
was undertaken for an eight-week period. Adult patients
(> = 18 years) presenting for their renal clinic appoint-
ment in a large, urban hospital, were asked about their
willingness to take part in the survey. Those agreeing
were given a package containing the survey, consent,
background information and postage-paid return enve-
lope. Participants were invited to return the survey to a
box in the clinic waiting area, to any clinic staff member,
or via regular mail after leaving the clinic. Return of the
survey was taken to be an indication of implied consent
as explained in the consent document.
The quantitative results were summarized using fre-
quencies and proportions. The latter were reported as
actual percentages, with those not responding to a given
item still included in the denominator. To conduct tests
for associations, the response options “strongly agree” and
“agree” were collapsed into one category and “strongly
disagree” and “disagree” were collapsed. Opinions on con-
sent and specific participant characteristics were assessed,
using chi-square (SPSS version 21). Opinions about the
use of health information compared to use of biospeci-
mens were also compared (chi-squares). The qualitative,




Eight hundred and forty-eight patients were invited to
participate, 448 declined. Of the 400 who agreed, 211
returned completed surveys (response rate of 24.9 %
overall, response rate of 52.8 % for surveys distributed).
Sample characteristics
Socio-demographic and health-related characteristics of
the participants are summarized in Table 1. Gender was
evenly split (46.4 % male, 44.1 % female, 9.5 % preferred
not to answer), participants were on average 59 years
old and most had some post secondary education
(70.2 %). Kidney biopsy status and the length of time
participants had been patients at the clinic were used
as indicators of illness severity. Using these variables,
more than half of the participants could be considered
as having chronic illness. Considering past research
participation, one quarter of participants indicated they
had previously taken part in research. Table 2 provides
a description of the research characteristics.
Health information
Participants were asked to describe the extent to which
they agreed with a series of statements about consent,
research and health information (Table 3). Almost all
participants agreed that promoting medical research was
an important goal for the community (97.2 %) and most
trusted medical researchers (82.5 %) to use their identifi-
able information respectfully. Moreover, most (79.6 %)
trusted REBs to decide when consent was needed.
Despite assurances that de-identified data meant their
identities would not be known, and despite recognizing that
challenges with obtaining consent might compromise re-
search (items 4 and 8) two-thirds of respondents (67.2 %)
believed individuals should always be asked if their de-
identified information could be used for medical research.
In contrast to the provisions of the HIA, most partici-
pants (65.9 %) believed where individuals could not give
their own consent, it was permissible to obtain consent
from a family member. Also in contrast to the HIA,
46.4 % agreed that a verbal consent was acceptable.
Several variables were examined for their potential
influence on consent for use of their identifiable or de-
identified information (age, education, ethnicity, experi-
ence with research, gender, income, illness severity). Two
associations were significant. Participants with less educa-
tion and those who were younger were more likely to
always give researchers consent for use of their identifiable
information (p = 0.034 and p = 0.001 respectively).
Participants were next asked to provide their level of
agreement with a series of statements about the use of
their health information and biospecimens (Table 4).
Although most participants agreed they would always
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give consent for their identifiable health information
(61.1 %) or biospecimens (57.3 %) to be used for any
medical research purpose, substantial proportions indi-
cated they would need to know the exact purpose
(45.5 % for health information; 29.9 % for biospecimens)
before giving consent, or that they would only consent
to permitting research on their specific health issues
(41.7 % for health information; 37.9 % for biospecimens).
Most agreed they should be given the opportunity to
change their minds and revoke consent (61.2 % for
health information, 61.1 % for biospecimens).
Most participants were comfortable with the uncon-
sented use of de-identified health information (63.5 %)
or biospecimens (61.2 %). While significant proportions
of participants wanted to know when their information
or biospecimens were used for research, there was vari-
ation that related to the identifiability of the material as
well as whether it was health information or biospeci-
mens that were used.
Across items, there were statistically significant differ-
ences in the opinions people offered for use of biospeci-
mens compared to health information (Table 5).
Qualitative data
Thirty-three people provided brief comments. The main
theme arising was that of altruism and desire to contrib-
ute to better care for others by permitting the use of
their information or specimens for research. (“I feel if my
specimens are of benefit to finding cures or improving
quality of life for our community then it should be freely
used;” “If others could benefit from the use of my informa-
tion, it would be a good thing. I have no problem with it”).
People also commented on the value and importance of
research (“I feel research is necessary to advance the med-
ical field…”), the preference that consent be sought (“….the
individual still has the right to choose”) and a few com-
ments reflecting concern that uses of information might
not be congruent with individual beliefs or may be used by
others such as insurers or governments (“The nature of the
research is important to me; it does not have to be about
my illness or condition however, there are types of research
I would not support;" “I believe medical research and use of
Table 1 Participant characteristics
Variable N (% of those
responding)
Gender
male 98 (46.4 %)
female 93 (44.1 %)
preferred not to answer 20 (9.5 %)
Age
mean 58.9 (SD = 17.3)
median 58
preferred not to answer 27 (12.8 %)
Education
high school or less 37 (17.5 %)




post secondary complete 61 (28.9 %)




<= 40 000.00 43 (20.4 %)
$40 000 < $60 000 29 (13.7 %)
$60 000 < $80 000 27 (12.8 %)
$80 000 < $100 000 19 (9.0 %)
>$100 000 33 (15.6 %)




Canadian 12 (5.0 %)
European Canadian 121 (57.3 %)
African Canadian 5 (2.4 %)
Asian Canadian 13 (6.2 %)
First Nations 3 (1.4 %)
other 27 (12.8 %)
preferred not to answer/
did not answer
42 (19.9 %)
Ever had kidney biopsy
yes 116 (55.0 %)
no 66 (31.3 %)
preferred not to answer 29 (13.7 %)
Affiliated with kidney clinic for
less than one year 19 (9.0 %)
1–5 years 83 (39.3 %)
6–10 years 28 (13.3 %)
more than 10 years 20 (9.5 %)
first visit 34 (16.1 %)
prefer not to answer/
did not answer
27 (12.8 %)
Table 2 Characteristics of previous research participation for
past participants (N = 53)
Research included N (%)
drug or other medical treatment
(e.g., counseling, exercise program)
14 (25.9 %)
imaging information (e.g., x-ray, MRI, CT scan) 5 (9.3 %)
tissues samples (e.g., blood, urine, stool, tumor) 12 (22.2 %)
personal health information (e.g., chart, medical records) 25 (47.2 %)
surveys, questionnaires, interviews 20 (37.7 %)
do not remember 10 (18.9 %)
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personal health info and biospecimens is necessary and
useful. However it needs to be handled responsibly. I would
not want the info to be used in other areas to separate or
disqualify in other areas such as insurance policies").
For a few people, while consent was not believed to be
necessary, being advised their information had been used
was important (“I would like to know if my information
is being used. It would make no difference why or to what
research its being applied”).
Discussion
In general, these patient participants were supportive of
medical research and very trusting of medical researchers.
Most believed that consent should be sought for use of
health information or biospecimens and most indicated
they would always give consent for any medical research.
This is consistent with the reports of others [11, 17, 21].
While some participants have discussed the need to retain
control over their information or material through a con-
sent process, our findings suggest that for a substantial
proportion of people, knowing their information or bios-
pecimens were being used for research purposes was suffi-
cient. As noted by others, a wide range of opinions was
given, making it difficult to suggest a single approach to
engaging people in sharing of these valuable research
resources [16, 18, 21].
The overall response rate for the study was 24.9 %. This
increased to 52.8 % for those who agree to take the survey
package for consideration. Correspondingly, the findings
are potentially limited by the respondents who were
already positively disposed towards research self-selecting
into the study. Together with these respondents being
from a unique patient population in a single clinic, the re-
sults may not be representative of the general population.
Health information
Congruent with the provisions of the Health Information
Act, over two thirds of the sample appreciated that
consent requirements could preclude, or limit the use-
fulness of, medical research. The remaining participants
either disagreed or did not hold an opinion. Despite the
background information provided, this may reflect lim-
ited understanding of research and concomitant privacy
standards, suggesting a need for public education in this
area. Limited patient or public understanding of research
and the use of health information has been previously re-
ported with similar calls for education arising [13, 15, 19].
Contrasting with provisions of the Health Information
Act, two thirds of the sample believed in the absence of
their own ability to give consent for health information
access, it should be permissible for consent to be obtained
from a family member (i.e., a surrogate). Currently, unless
there is a specific, written authorization in place to this
effect (i.e., a research directive) the HIA prohibits consent
from another s104(i), leaving it to REBs to consider grant-
ing a waiver where people lack capacity or are otherwise
unable to consent. Whereas surrogate decisions might be
made based on what they believe their family members
Table 3 Participant opinions on research, consent and use of health information
Statement Strongly
Disagree %
Disagree % Neutral % Agree % Strongly
Agree %
1. Promoting good medical research is an important goal for the community 1.4 0.5 0 31.3 65.9
2. Sometimes medical research cannot be undertaken without using individuals
identifiable health information
3.8 5.2 13.7 55.5 19.0
3. I trust Research Ethics Boards to make decisions about when individuals’ consent
for use of their identifiable health information for research is necessary
0 2.4 16.6 50.7 28.9
4. Sometimes, getting an individual’s consent to use identifiable health information for
research might be so difficult that it would prevent the research from being done
1.9 8.1 18.5 51.7 16.1
5. If consent can only be obtained from some individuals and therefore only some
information can be gathered, the research results might not be as useful
0.9 10.4 12.3 53.1 20.4
6. Individuals should always be asked if their de-identified health information can be
used for medical research
7.1 11.4 11.4 44.5 22.7
7. Individuals should always be asked if their identifiable health information can be
used for medical research
2.8 2.4 12.3 45.0 34.6
8. Consent must be obtained in writing or by electronic means (i.e., by email) for
it to be OK
3.8 13.3 17.1 41.7 21.3
9. It is OK to obtain consent verbally (i.e., over the phone, or in fact to face discussion) 6.6 25.1 19.4 37.9 8.5
10. When individuals are unable to give their own consent, it is OK to get consent
from a family member
3.8 11.8 15.2 54.5 11.4
11. There are risks from researchers using identifiable health information 4.7 16.6 30.3 39.3 6.6
12. There are benefits from researchers using identifiable health information 0.9 4.7 9.0 53.1 29.4
13. I trust medical researchers to use identifiable health information respectfully 0 0.9 13.7 52.6 29.9
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would have wanted or possibly their family member’s best
interests, REBs make the decision based on the feasibility
of obtaining an individual consent. If the prospective par-
ticipant cannot make this decision due to limitations of
capacity, or due to mortality, it is clearly not feasible to
obtain their consent. In such circumstances, REBs must
favour the utility of non-consensual data use, where public
interest outweighs individual privacy interests, if the
information is to be released. While this is intended to
maximize the good coming from use of this informa-
tion, it does so at the expense of individual preference
as understood by a surrogate. Although this survey sought
opinion on the validity of surrogate consents, it did not
assess people’s awareness of the current standard. A better
Table 4 Participant opinions on research use of health information and biospecimens
Statement Strongly
Disagree %
Disagree % Neutral % Agree % Strongly
Agree %
1. I would always give medical researchers consent to use my identifiable
health information or biospecimens for any medical research purpose
health information 4.7 18.0 15.2 43.1 18.0
biospecimen 3.8 14.2 22.7 41.7 15.6
2. I need to know the exact medical research purpose for which my identifiable
health information or biospecimen is being used before I would give consent
health information 9.0 21.8 21.8 33.2 12.3
biospecimen 10.4 34.1 23.2 23.7 6.2
3. It is enough for me to know my identifiable health information or biospecimen
is being used for medical research in general
health information 3.3 15.6 20.4 46.9 12.0
biospecimen 3.8 14.2 17.1 47.4 14.7
4. I would consent to have my identifiable health information or biospecimens held
in a research repository, data library or biobank and used as needed by researchers
health information 1.9 12.8 14.2 50.2 18.0
biospecimen 3.3 9.0 15.2 53.1 17.1
5. I would give consent to use my identifiable health information or biospecimen for
research only on my specific health/illness issues
health information 7.6 28.9 20.4 33.6 8.1
biospecimen 6.6 29.4 23.7 30.8 7.1
6. I need to know the identity of the person to whom my identifiable health information/
biospecimen is being given before I would give consent
health information 11.8 41.2 23.2 18.0 4.3
biospecimen 13.7 44.1 20.9 13.3 5.2
7. I am comfortable with medical researchers using my de-identified health information or
biospecimens without my consent
health information 6.6 16.6 10.9 40.8 22.7
biospecimen 4.3 16.6 16.1 40.3 20.9
8. I believe I should be given the opportunity to change my mind and take back my
consent once I have given it
health information 3.3 11.8 22.3 42.2 19.0
biospecimen 3.8 9.5 22.7 43.1 18.0
9. I would like to know when my identifiable health information or biospecimens are
used for medical research
health information 5.7 16.6 26.5 36.5 13.3
biospecimen 7.6 26.5 20.4 34.6 8.1
10. I would like to know when my de-identified health information or biospecimens
are used for medical research
health information 9.5 28.9 24.6 27.5 7.6
biospecimen 13.3 32.2 19.0 28.0 4.3
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understanding of pubic perceptions would inform future
public education and legislative revisions.
More than half of those expressing an opinion about the
form consent should take agreed that it could be oral as
opposed to written. This preference is again at odds with
the provisions of the Health Information Act, although as
with surrogate consent, it is consistent with the TCPS2.
Alignment of these regulatory requirements would facili-
tate more consistency in the application and acceptance of
research ethics standards.
While the Health Information Act requires a specific re-
search purpose be given for the use of health information





1. I would always give medical researchers consent to use my identifiable
health information or biospecimens for any medical research purpose *
health information 23.1 (48) 62.0 (129)
biospecimen 18.4 (38) 58.7 (121)
2. I need to know the exact medical research purpose for which my identifiable
health information or biospecimen is being used before I would give consent *
health information 31.6 (65) 46.6 (96)
biospecimen 45.9 (94) 30.7 (63)
3. It is enough for me to know my identifiable health information or biospecimen
is being used for medical research in general *
health information 19.4 (40) 60.2 (124)
biospecimen 18.6 (38) 64.2 (131)
4. I would consent to have my identifiable health information or biospecimens held
in a research repository, data library or biobank and used as needed by researchers *
health information 15.1 (31) 70.5 (144)
biospecimen 12.7 (26) 72.2 (148)
5. I would give consent to use my identifiable health information or biospecimen for
research only on my specific health/illness issues *
health information 37.2 (77) 42.5 (88)
biospecimen 37.1 (76) 39.0 (80)
6. I need to know the identity of the person to whom my identifiable health
information/biospecimen is being given before I would give consent *
health information 54.1 (112) 22.7 (47)
biospecimen 59.8 (122) 19.1 (39)
7. I am comfortable with medical researchers using my de-identified health information
or biospecimens without my consent
health information 23.9 (49) 65.4 (134)
biospecimen 21.4 (44) 62.6 (129)
8. I believe I should be given the opportunity to change my mind and take back my
consent once I have given it *
health information 15.5 (32) 62.3 (129)
biospecimen 13.7 (28) 63.2 (129)
9. I would like to know when my identifiable health information or biospecimens are
used for medical research
health information 22.7 (47) 50.7 (105)
biospecimen 35.3 (72) 44.1 (90)
10. I would like to know when my de-identified health information or biospecimens
are used for medical research
health information 39.3 (81) 35.9 (74)
biospecimen 46.6 (96) 33.0 (68)
P < 0.005
*significant at p <0.005 (Chi Square)
Page et al. BMC Medical Ethics  (2016) 17:48 Page 7 of 9
(s34), over half of respondents indicated they did not need
to know the exact purpose or had no opinion. Even fewer
people seemed interested in this level of detail for biospe-
cimen use. This suggests that most people are comfortable
providing a broad, or general consent and is consistent
with the reports of others [15, 18]. In line with our find-
ings, the US Department of Health and Human Services
(HHS) advanced changes to the Health Insurance Port-
ability and Accountability Act (HIPAA) in 2013 that allow
“compound authorizations” (i.e., consents) for the use of
health information for future, unspecified research pur-
poses, as long as a reasonably informed decision can be
made [26]. In contrast to use being for any purpose what-
soever (i.e., a blanket consent), providing a general re-
search direction is viewed as sufficient to permit a valid
exercise of autonomy (i.e., a broad consent).
An inconsistency was observed in opinions on the
need for consent and use of deidentified data. While
most respondents indicated that “individual” consent
should always be sought for the use of de-identified
health information (i.e., Table 3, item 6), most also in-
dicated they personally (i.e., “I”) were comfortable with
use of their de-identified information without their con-
sent (i.e., Table 4, item 7). This may reflect respondents
making a distinction between the “other” and the self on
this issue, or it may reflect an ambiguous opinion. This
finding has implications for the wording of future survey
items and is an area worth exploring further.
Biospecimens
Consistent with the above and with current guidance
under TCPS2 (2014), most participants were comfortable
with the nonconsensual use of deidentified biospecimens.
However, over one-third of those responding were either
unsure or were not comfortable with this lack of consent
(Table 4, item 7). Taken together with a significant propor-
tion of people indicating they would like to know when
their deidentified health information or biospecimens are
used for research, such discomfort raises the possibility of
public backlash at the presumptive use of their informa-
tion, should they become aware of such activities. Without
transparency in the research process, either through the
provision of information that deidentified data or biospeci-
mens are being used or a formal consent process, there is
the potential for individuals to feel that research is being
undertaken in secrecy. This perception could foster mis-
trust, ultimately undermining public support of future re-
search. The United States Department of Health and
Human Services released a Notice of Proposed Rule Mak-
ing (Sept 8, 2015) that, if brought into effect, would
mandate consent for use of de-identified biospecimens [7].
However, as with health information, broad consent would
be acceptable, permitting future unspecified uses on the
basis of the initial consent. Permitting broad consents
seeks to balance individuals’ rights to authorize use of their
personal health data/biospecimens while reducing the bur-
dens for both researchers and participants associated with
obtaining project-specific (i.e., narrow) consent.
Health information and biospecimens
The results on research use of biospecimens compared to
health information revealed statistically significant differ-
ences in opinions. These differences were not consistently
more restrictive for one source of data vs. the other. It is not
clear how relevant or meaningful these differences are in
reality, given the general similarity in proportions. Address-
ing this directly in future research would be informative.
Conclusion
This study described the opinions of patient participants
on the research use of their health information and bios-
pecimens considered in the context of current standards.
Clinical health data and biospecimens are valuable re-
search resources, critical to the advancement of medicine.
Use of these data for research requires balancing respect
for individual autonomy, privacy and the societal interest
in the greater good. Both the TCPS2 and the Health Infor-
mation Act recognize this trade-off by providing processes
where the usual consent requirements can be waivered or
altered. This research revealed that these participant mem-
bers of the public did not always share the positions on
consent that are upheld by the HIA and the TCPS2.
Research using clinical data, including health records and
biospecimens has increased dramatically over the past
decade and greater consideration is being given to the
rights of those who provide these research resources. Rec-
ognizing that respecting the individual preferences is not
always feasible, these findings have implications for the
regulation of research access to health information and
biospecimens. If regulations are intended to reflect the pref-
erences of the majority of population they are intended to
protect, Canadian standards should be reviewed, with con-
sideration given to permitting broad consents and to
requiring consent for access to de-identified biospecimens.
Finally, public education should be encouraged to a greater
extent so that understanding, transparency and trust is
fostered regarding research uses of health information and
biospecimens.
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